Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19.
Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19.
复制标题
DOI：
10.1016/j.vaccine.2021.08.088
复制
发表时间：
2021-09-24
期刊：
影响因子：
5.5
通讯作者：
Rotlevi E
中科院分区：
文献类型：
--
作者：
Brosh-Nissimov T;Sorek N;Yeshayahu M;Zherebovich I;Elmaliach M;Cahan A;Amit S;Rotlevi E
在接种BNT162b2疫苗后，贝尔麻痹、单纯疱疹和带状疱疹的增加引起了人们的关注，所有这些都是疱疹病毒重新激活的表现。由于疱疹病毒通常在口咽部重新激活，我们假设接种疫苗后口咽中疱疹病毒的脱落会增加。在接种BNT162b2疫苗前和接种后一周，对免疫能力正常的成年人(不包括使用局部类固醇或表现出有症状的疱疹病毒感染的人)进行采样。用多重聚合酶链式反应检测疱疹病毒1-7脱落物。在103对样本中，接种前后疱疹病毒的感染率相似：HSV1，3.9%对5.8%(p=0.75)；HSV2，0%对1%(p=0.55)；VZV，0%对0%(p=1NA)；EBV，14.6%对17.5%(p=40.63)；CMV，0%对0%(p=0.55)；HHV6，4.9%对7.8%(p=0.55)；HHV7，71.8%vs.72.8%(p=0.1.)；任何疱疹病毒，73.8%vs.74.8%(p=0.1.)。我们没有发现BNT162b2治疗一周后口咽部疱疹病毒活性增加的证据。
Concerns were raised over an increase in Bell's palsy, herpes simplex and herpes zoster after BNT162b2 vaccination, all are manifestations of herpesviruses reactivation. As herpesviruses commonly reactivate in the oropharynx, we have hypothesized that oropharyngeal shedding of herpesviruses will increase after vaccination. Immune-competent Adults, excluding those using topical steroids or manifesting symptomatic herpesvirus infection, were sampled before BNT162b2 vaccination and one week after. Herpesviruses 1–7 shedding was tested with a multiplexed PCR. In 103 paired samples the prevalence of herpesviruses was similar before and after vaccination: HSV1, 3.9% vs. 5.8% (p = 0.75); HSV2, 0% vs. 1% (p = not applicable, NA); VZV, 0% vs. 0% (p = NA); EBV, 14.6% vs. 17.5% (p = 0.63); CMV, 0% vs. 0% (p = NA); HHV6, 4.9% vs. 7.8% (p = 0.55); HHV7, 71.8% vs. 72.8% (p = 1); any herpesvirus, 73.8% vs. 74.8% (p = 1). We did not find evidence for increased oropharyngeal reactivation of herpesviruses one week after BNT162b2.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
4.9
作者：
Shin, So Youn;Kwon, Kye Chul;Koo, Sun Hoe
通讯作者：
Koo, Sun Hoe
影响因子：
--
作者：
Rodríguez-Jiménez P;Chicharro P;Cabrera LM;Seguí M;Morales-Caballero Á;Llamas-Velasco M;Sánchez-Pérez J
通讯作者：
Sánchez-Pérez J
DOI：
10.1016/j.bbih.2021.100217
发表时间：
2021-05
期刊：
Brain, behavior, & immunity - health
影响因子：
--
作者：
Repajic M;Lai XL;Xu P;Liu A
通讯作者：
Liu A
影响因子：
1.4
作者：
Peitersen, E
通讯作者：
Peitersen, E